The company submitted a New Drug Application to the United States Food and Drug Administration in December 2025, based on the REDEFINE 1 and REDEFINE 2 results, with a decision anticipated late in 2026
The only combined-use human data is a small, low-quality intra-articular case series at higher, different-route doses not this subcutaneous blend
This unique mechanism enables BPC-157 to promote healing throughout the entire wound repair process from initial inflammation through final tissue remodeling phases
Managing Side Effects in Combination Protocols When researching a cagrilintide blend with retatrutide , the overlapping gastrointestinal effects require proactive management strategies: Dietary Modifications: Smaller, more frequent meals to reduce gastric burden Avoiding high-fat foods that slow digestion further Adequate hydration to support digestive function Limiting alcohol and caffeine intake Timing Strategies: Administering doses in the evening to sleep through peak nausea periods Staggering cagrilintide and retatrutide administration by several days Taking doses after light meals rather than on an empty stomach Supplemental Support: Ginger supplements or tea for nausea management Probiotics to support gut health Electrolyte supplementation if experiencing vomiting or diarrhea Researchers working with metabolic peptides can find additional safety information through resources on peptide quality standards and proper research protocols
Any decision to incorporate peptide-based therapies is made collaboratively between physician and patient, with a focus on safety, transparency, and evidence-informed care
